3,751 results match your criteria: "Goodman Cancer Centre; McGill University[Affiliation]"
Int J Chron Obstruct Pulmon Dis
September 2024
College of Medicine, Section of Cardiology, University of Manitoba, Winnipeg, Manitoba, Canada.
Background: In Canada, COPD represents a significant burden to the patient and health system, as it is often under or misdiagnosed and sub-optimally treated. Cardiovascular disease (CVD) is a common co-morbidity in COPD and there is significant interplay between these two chronic conditions. Across all stages of COPD disease severity, deaths can be attributed not only to respiratory causes but also to cardiovascular-related factors.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
October 2024
Department of Microbiology and Immunology, McGill University, Montréal, QC H3A 2B4, Canada.
In the lower respiratory tract, the alveolar spaces are divided from the bloodstream and the external environment by only a few microns of interstitial tissue. Alveolar macrophages (AMs) defend this delicate mucosal surface from invading infections by regularly patrolling the site. AMs have three behavior modalities to achieve this goal: extending cell protrusions to probe and sample surrounding areas, squeezing the whole cell body between alveoli, and patrolling by moving the cell body around each alveolus.
View Article and Find Full Text PDFPrev Med Rep
October 2024
Centre for Chronic Disease Control, New Delhi, India.
Introduction: Region-specific data on individual factors associated with uptake of breast and cervical cancer screening or early testing in diverse Indian populations are limited.
Aim: To assess the prevalence and individual determinants of uptake of breast and/or cervical cancer screening or testing among women aged 30-69 years in regionally representative populations of two large Indian cities: New Delhi and Chennai.
Methods: We conducted an analysis of the cross-sectional data (2016-2017) nested within the Centre for Cardiometabolic Risk Reduction in South Asia cohort, established in 2010-2011 with 12,271 participants (5365 in New Delhi; 6906 in Chennai).
Cannabis Cannabinoid Res
September 2024
Department and Anatomy and Neurobiology, University of California, Irvine, California, USA.
J Integr Complement Med
September 2024
UPMC Health Services Division, Pittsburgh, Pennsylvania, USA.
Lancet
October 2024
Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06511, USA; Department of Pathology, Yale School of Medicine, New Haven, CT 06511, USA; Department of Urology, Yale School of Medicine, New Haven, CT 06511, USA; Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT 06511, USA. Electronic address:
N Engl J Med
January 2025
From the Sandra and Edward Meyer Cancer Center (J.D.W.) and the Department of Medicine (J.D.W., M.A.P.), Weill Cornell Medicine, and Memorial Sloan Kettering Cancer Center (M.A.P.) - both in New York; Istituto Oncologico Veneto, IRCCS, Padua (V.C.-S.), European Institute of Oncology, IRCCS, Milan (P.Q.), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola (M.G.), University of Siena and the Center for Immuno-Oncology, University Hospital of Siena, Siena (M.M.), and Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples (P.A.A.) - all in Italy; Maria Sklodowska-Curie National Institute of Oncology, Warsaw, Poland (P.R.); Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas (C.L.C.); University Hospital Essen, the German Cancer Consortium, the National Center for Tumor Diseases-West, the Research Alliance Ruhr, Research Center One Health, and University Duisburg-Essen - all in Essen, Germany (D.S.); the College of Medicine, Swansea University, Swansea (J.W.), Bristol Myers Squibb, Uxbridge (A.N.), and the Royal Marsden Hospital, London (J.L.) - all in the United Kingdom; the Department of Dermatology, University of Zurich, Zurich, Switzerland (R.D.); University Health Network Princess Margaret Cancer Centre, Toronto (M.O.B.), and Cross Cancer Institute, University of Alberta, Edmonton (J.W.) - both in Canada; Tasman Oncology Research, Southport, QLD (A.G.H.), Westmead Hospital, Westmead, NSW (M.S.C.), Blacktown Hospital, Blacktown, NSW (M.S.C.), the Melanoma Institute Australia, University of Sydney (M.S.C., G.V.L.), Royal North Shore Hospital (G.V.L.), and Mater Hospital (G.V.L.), Sydney, and Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC (S.S.) - all in Australia; Aix-Marseille Université, Assistance Publique-Hôpitaux de Marseille, Marseille (C.G.-M.), and Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP) Dermato-oncology, Clinical Investigation Center, the Cancer Institute, AP-HP Nord Paris Cité, INSERM Unité 976, and St. Louis Hospital, Paris (C.L.) - all in France; the University of Colorado Cancer Center, Aurora (T.M.); Rogel Cancer Center, University of Michigan, Ann Arbor (C.D.L.); Hospital General Universitario Gregorio Marañon, Madrid (I.M-R.); the Netherlands Cancer Institute, Amsterdam (J.B.A.G.H.); University Hospital Leuven and Leuven Cancer Institute, KU Leuven, Leuven, Belgium (P.S.); Bristol Myers Squibb, Princeton, NJ (C.R., M.A., M.P.B., W.W.); and Dana-Farber Cancer Institute, Boston (F.S.H.).
Background: Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy in patients with advanced melanoma. Given that patients with advanced melanoma are living longer than 7.5 years, longer-term data were needed to address new clinically relevant questions.
View Article and Find Full Text PDFSequential adaptive trial designs can help accomplish the goals of personalized medicine, optimizing outcomes and avoiding unnecessary toxicity. Here we describe the results of incorporating a promising antibody-drug conjugate, datopotamab-deruxtecan (Dato-DXd) in combination with programmed cell death-ligand 1 inhibitor, durvalumab, as the first sequence of therapy in the I-SPY2.2 phase 2 neoadjuvant sequential multiple assignment randomization trial for high-risk stage 2/3 breast cancer.
View Article and Find Full Text PDFAmong the goals of patient-centric care are the advancement of effective personalized treatment, while minimizing toxicity. The phase 2 I-SPY2.2 trial uses a neoadjuvant sequential therapy approach in breast cancer to further these goals, testing promising new agents while optimizing individual outcomes.
View Article and Find Full Text PDFJ Stroke
September 2024
School of Medicine, New York Medical College, Valhalla, NY, USA.
Background And Purpose: Cerebral venous thrombosis (CVT) is associated with a high degree of morbidity and mortality. Our objective is to elucidate characteristics, treatments, and outcomes of patients with cancer and CVT (CA-CVT).
Methods: The 2016-2019 National Inpatient Sample (NIS) database was queried for patients with a primary diagnosis of CVT.
Neuroimage
October 2024
McConnell Brain Imaging Centre, Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada; Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada; Department of Biomedical Engineering, McGill University, Montreal, Quebec, Canada. Electronic address:
Non-invasive myelin water fraction (MWF) and g-ratio mapping using microstructural MRI have the potential to offer critical insights into brain microstructure and our understanding of neuroplasticity and neuroinflammation. By leveraging a unique panel of variably hypomyelinating mouse strains, we validated a high-resolution, model-free image reconstruction method for whole-brain MWF mapping. Further, by employing a bipolar gradient echo MRI sequence, we achieved high spatial resolution and robust mapping of MWF and g-ratio across the whole mouse brain.
View Article and Find Full Text PDFPEC Innov
December 2024
Center for Anti-racism, Social Justice & Public Health, New York University School of Global Public Health, New York, NY 10003, USA.
Objective: To analyze the relationship between perceived discrimination over the life course, social status, and limited health literacy (HL).
Methods: 5040 adults who participated in the 2023 Survey of Racism and Public Health. We applied stratified multilevel models adjusted for sociodemographic characteristics.
Cell Rep
September 2024
Rosalind and Morris Goodman Cancer Institute, McGill Centre for RNA Sciences & Department of Biochemistry, McGill University, Montréal, QC H3G 1Y6, Canada. Electronic address:
MicroRNAs (miRNAs) play crucial roles in physiological functions and disease, but the regulation of their nuclear biogenesis remains poorly understood. Here, BioID on Drosha, the catalytic subunit of the microprocessor complex, reveals its proximity to splicing factor proline- and glutamine (Q)-rich (SFPQ), a multifunctional RNA-binding protein (RBP) involved in forming paraspeckle nuclear condensates. SFPQ depletion impacts both primary and mature miRNA expression, while other paraspeckle proteins (PSPs) or the paraspeckle scaffolding RNA NEAT1 do not, indicating a paraspeckle-independent role.
View Article and Find Full Text PDFImportance: Increasing numbers of unaffected individuals could benefit from genetic evaluation for inherited cancer susceptibility. Automated conversational agents (ie, chatbots) are being developed for cancer genetics contexts; however, randomized comparisons with standard of care (SOC) are needed.
Objective: To examine whether chatbot and SOC approaches are equivalent in completion of pretest cancer genetic services and genetic testing.
Int J Biol Sci
September 2024
C.A.I.R. Institute, The Safdiè AIDS and Immunology Research Center, The Mina & Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel.
Various cancer treatment approaches that inhibit the activity of the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis, a key player in tumor immune evasion, have been developed. We show that the immunomodulatory small tellurium complexes AS101 (ammonium trichloro(dioxoethylene-o,o')tellurate) and SAS (octa-O-bis(R,R)-tartarate ditellurane) suppress PD-L1 expression in a variety of human and mouse malignant cells via the modulation of α4β1 very late antigen- (VLA-4) integrin activity. Consequently, the expression of pAkt and its downstream effector pNFκB are inhibited.
View Article and Find Full Text PDFBMC Palliat Care
September 2024
Department of Oncology, London Health Sciences Centre, Western University, 800 Commissioners Rd. E, London, ON, N6A 5W9, Canada.
Int J Radiat Oncol Biol Phys
October 2024
Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Int J Radiat Oncol Biol Phys
October 2024
Department of Radiation Oncology, Icahn School of Medicine, Mount Sinai University.
Nat Commun
September 2024
Department of Human Genetics, McGill University, Montreal, QC, H3A 0C7, Canada.
Histone H3-mutant gliomas are deadly brain tumors characterized by a dysregulated epigenome and stalled differentiation. In contrast to the extensive datasets available on tumor cells, limited information exists on their tumor microenvironment (TME), particularly the immune infiltrate. Here, we characterize the immune TME of H3.
View Article and Find Full Text PDFEBioMedicine
October 2024
Department of Biostatistics, University of Washington, Seattle, WA, USA; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. Electronic address:
Background: The HVTN 705 Imbokodo trial of 2636 people without HIV and assigned female sex at birth, conducted in southern Africa, evaluated a heterologous HIV-1 vaccine regimen: mosaic adenovirus 26-based vaccine (Ad26.Mos4.HIV) at Months 0, 3, 6, 12 and alum-adjuvanted clade C gp140 at Months 6, 12.
View Article and Find Full Text PDFOncologist
September 2024
Division of Hematology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States.
Background: Smoldering multiple myeloma (SMM), an asymptomatic precursor of multiple myeloma (MM), carries a variable risk of progression to MM. There is little consensus on the efficacy or optimal timing of treatment in SMM. We systematically reviewed the landscape of all clinical trials in SMM.
View Article and Find Full Text PDFJ Natl Cancer Inst
September 2024
Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
JAMA Netw Open
September 2024
Cancer Research Program, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
Importance: Metastatic breast cancer (MBC) poses a substantial clinical challenge despite advancements in diagnosis and treatment. While tissue biopsies offer a static snapshot of disease, liquid biopsy-through detection of circulating tumor DNA (ctDNA)-provides minimally invasive, real-time insight into tumor biology.
Objective: To determine the association between ctDNA and survival outcomes in patients with MBC.
Arch Gynecol Obstet
November 2024
EU Real World Evidence, Xcenda GmbH, Lange Laube 31, 30159, Hanover, Germany.
Radiology
September 2024
From the Departments of Surgery, Colorectal Service (H.W., D.M.O., H.M.T., F.S.V., J.B.Y., J.B., M.R.M., J.G.A.), Epidemiology and Biostatistics (S.T.L., L.X.Q.), and Radiology (J.M., M.J.G.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Department of Radiology, University of Rochester Medical Center, Rochester, NY (D.A.D.); Department of Radiology, University of South Florida, Tampa, Fla (R.K.); Department of Radiology, University of Chicago, Chicago, Ill (A.O.); Department of Radiology, Oregon Health and Science University, Portland, Ore (E.K.); Department of Radiology, Cleveland Clinic, Cleveland, Ohio (J.C.V.); Department of Radiology, John Muir Health, Walnut Creek, Calif (S.G.); Department of Radiology, University of Virginia, Charlottesville, Va (A.K.); Department of Radiology, University of Washington, Seattle, Wash (M.J.); Department of Radiology, St Joseph Hospital Orange County, Orange, Calif (K.O., D.V.); Department of Radiology, University of California San Francisco, San Francisco, Calif (T.A.H.); Department of Radiology, University of California Irvine, Irvine, Calif (S.L.); Department of Radiology, University of Michigan, Ann Arbor, Mich (A.P.W.); and Department of Radiology, University of Colorado Anschutz Medical Campus, Aurora, Colo (N.M.).
Background MRI plays a crucial role in restaging locally advanced rectal cancer treated with total neoadjuvant therapy (TNT); however, prospective studies have not evaluated its ability to accurately select patients for nonoperative management. Purpose To evaluate the ability of restaging MRI to predict oncologic outcomes and identify imaging features associated with residual disease (RD) after TNT. Materials and Methods This was a secondary analysis of the Organ Preservation in Rectal Adenocarcinoma (OPRA) trial, which randomized participants from April 2014 to March 2020 with stages II or III rectal adenocarcinoma to undergo either induction or consolidation TNT.
View Article and Find Full Text PDF